Danish Biotech Company sees Huge Potential in new Semen Test  

The Danish biotech company, SPZ Lab, has developed a new diagnostic semen test, which will enable involuntarily childless couples to find the right treatment.
The semen test consists of complicated procedures, which will enable childless couples to find out which fertility treatment is right for them, if any. In a socio economic light, this could mean great savings. SPZ Lab has already sold the test to the Netherlands, Germany, Ireland and Finland.
Says CEO and founder, Preben Christensen; ‘Our ambition is to hit a growth rate of 200-250 percent per year in order to as much of the market as possible within 5-10 years.’ 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×